Thus, the role of ROS, and to some extent NRF2 signaling, in shaping anti-tumoral immunity may explain inconsistent responses to auranofin in different models and guide more effective use of TXNRD1 inhibitors in cancer therapy. Here, TXNRD1 is linked to cancer.